A novel fecal antigen detection assay for fresh and frozen human samples that detects but does not differentiate Giardia spp, Cryptosporidium spp, and Entamoeba histolytica, the Tri-Combo parasite screen, was compared to three established enzymelinked immunosorbent assays (ELISAs) at three international sites. It exhibited 97.9% sensitivity and 97.0% specificity, with positive and negative predictive values of 93.4% and 99.1%, respectively. The Tri-Combo test proved a reliable means to limit the use of individual parasite ELISAs to positive samples.
While death from diarrheal infections has decreased, levels of morbidity have not declined in comparison to historical levels and thus remain a significant health problem, especially in the developing world (7,11). Three of the most common causes of protozoan-associated diarrheal infections are Giardia spp., Cryptosporidium spp., and Entamoeba histolytica (16). All three of these parasites are transmitted via a classical fecal-oral cycle (1). Cryptosporidium spp. are common throughout both the developed and developing world and can cause persistent diarrhea in HIV-infected individuals (2,12,19). Control of this organism can prove difficult due to its resistance to standard disinfection methods (e.g., chlorination of water sources) (3). E. histolytica is a singlecell ameba that is the cause of amebiasis (20). Clinical manifestations include diarrhea, dysentery, toxic megacolon, and liver abscess (5). The incidence of disease due to Cryptosporidium spp. and E. histolytica, and possibly Giardia spp., is increased with malnutrition (13,14). Repeated infections are common and can cause developmental delay in children (6, 15). Because treatment regimens for these infections are available, there is a need for rapid and cost-effective diagnostic screening methods (8,10,16,17).The Tri-Combo parasite screen test (TechLab, Blacksburg, VA), intended for clearance by the U.S. Food and Drug Administration (FDA), is an enzyme-linked immunosorbent assay developed to simultaneously detect Giardia spp., Cryptosporidium spp., and E. histolytica antigens in human fecal specimens. The microtiter plate format allows the rapid screening of large numbers of clinical specimens. Similar to other immunoassay-type tests for these three parasites, the Tri-Combo test is not designed for use with fixed fecal specimens. When a clinical sample is positive by the Tri-Combo test, additional testing for the presence of Giardia spp., Cryptosporidium spp., and/or E. histolytica parasites is indicated, as the test does not distinguish between these parasites.A panel of 618 diarrheal and nondiarrheal human fecal specimens from male and female subjects aged 4 months to 89 years were tested with the Tri-Combo test at three international sites: 87 clinical samples at the National Institute for Infectious Disease (NIID) in Tokyo, Japan; 297 clinical samples at the International Center for Diarrheal Disease Research, Bangladesh (ICDDR,B), in Dhaka, Bangladesh; and 234 clinical samples at the Bernard Nocht Insti...